Entera Bio Ltd. Ordinary Shares (ENTX) is a publicly traded Healthcare sector company. As of May 21, 2026, ENTX trades at $1.23 with a market cap of $60.55M and a P/E ratio of 4.97. ENTX moved +0.00% today. Year to date, ENTX is -29.94%; over the trailing twelve months it is -39.81%. Its 52-week range spans $0.91 to $3.22. Analyst consensus is buy with an average price target of $9.00. Rallies surfaces ENTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Entera Bio Eyes H2 2028 Topline with 750-Patient Phase 3 EB613 Trial: Entera Bio submitted a streamlined Phase 3 protocol for its oral EB613 osteoporosis tablet, enrolling 750 postmenopausal women with primary endpoint of 12-month hip BMD change, aiming for late-2026 initiation and potential topline data by H2 2028. The FDA granted Type A alignment and qualified BMD as a surrogate endpoint.
| Metric | Value |
|---|---|
| Price | $1.23 |
| Market Cap | $60.55M |
| P/E Ratio | 4.97 |
| EPS | $0.25 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.22 |
| 52-Week Low | $0.91 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $42.00K |
| Net Income | $-11.44M |
| Gross Margin | 0.00% |
1 analysts cover ENTX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.00.